| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/16/2003 | WO2003004531A2 Regulation of human somatostatin receptor-like protein |
| 01/16/2003 | WO2003004530A1 Regulation of human somatostatin receptor-like protein |
| 01/16/2003 | WO2003004527A2 Novel neurotrophic factors |
| 01/16/2003 | WO2003004526A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines |
| 01/16/2003 | WO2003004520A2 Mycobacterial antigens expressed during latency |
| 01/16/2003 | WO2003004518A2 Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors |
| 01/16/2003 | WO2003004517A2 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | WO2003004513A1 Antisense modulation of hkr1 expression |
| 01/16/2003 | WO2003004511A2 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 01/16/2003 | WO2003004479A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | WO2003004098A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | WO2003004091A2 Aromatic sulfenates for type i phototherapy |
| 01/16/2003 | WO2003004088A2 Method of administration of a gene of interest to the heart and vasculature |
| 01/16/2003 | WO2003004068A1 Hypertension treatment |
| 01/16/2003 | WO2003004067A1 Methods and compositions for the treatment and diagnosis of body weight disorders |
| 01/16/2003 | WO2003004066A1 Gene therapeutics |
| 01/16/2003 | WO2003004065A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 01/16/2003 | WO2003004064A2 Products for treating ovarian cancers and for preventing relapses |
| 01/16/2003 | WO2003004061A1 Uv-screening peptide-flavonoid conjugates |
| 01/16/2003 | WO2003004057A1 Ephrin and eph receptor mediated immune modulation |
| 01/16/2003 | WO2003004053A1 Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab |
| 01/16/2003 | WO2003004050A1 Methylation of histone h4 at arginine 3 |
| 01/16/2003 | WO2003004048A1 Compositions for nasal administration of insulin |
| 01/16/2003 | WO2003004047A1 Cell death inducers for mast cells |
| 01/16/2003 | WO2003004046A2 Use of xaa-pro peptidases for the treatment of substance p-related disorders |
| 01/16/2003 | WO2003004045A2 Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors |
| 01/16/2003 | WO2003004041A1 Therapeutic composition including saw palmetto for cancer treatment |
| 01/16/2003 | WO2003004034A1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| 01/16/2003 | WO2003004032A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | WO2003004031A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | WO2003004030A1 Oxymorphone controlled release formulations |
| 01/16/2003 | WO2003004004A1 Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 01/16/2003 | WO2003003988A2 Peptides which modulate blood coagulation and methods of use thereof |
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2003003977A2 Compositions and methods for the treatment of body weight disorders, including obesity |
| 01/16/2003 | WO2003003976A2 Compositions for removing human cerumen |
| 01/16/2003 | WO2003003971A2 Use of antidiabetics for making a medicine with cicatrizing effect |
| 01/16/2003 | WO2003003904A2 Coactivators in the diagnosis and treatment of breast cancer |
| 01/16/2003 | WO2003003855A1 Nutrition supplement or drug against specified deficiency conditions and cerebral dysfunctions |
| 01/16/2003 | WO2003003847A1 Methods of extracting casein fractions from milk and caseinates and production of novel products |
| 01/16/2003 | WO2002094194A3 Compositions and methods for inhibiting metastasis |
| 01/16/2003 | WO2002088178A3 Antigens of group b streptococcus and corresponding dna fragments |
| 01/16/2003 | WO2002077023A3 A new essential downstream component of the wingless signalling pathway |
| 01/16/2003 | WO2002072129B1 METHODS FOR REGULATING BUD-HYPHA TRANSITIONS AND cAMP LEVELS BY THE ADENYLATE CYCLASE-ASSOCIATED PROTEIN GENE, CAP1 |
| 01/16/2003 | WO2002070690A3 Abca5 transporter and uses thereof |
| 01/16/2003 | WO2002067968A3 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 01/16/2003 | WO2002066510A3 Regakine-1 |
| 01/16/2003 | WO2002059147A3 Activatable cytolytic or drug delivery peptides and uses thereof |
| 01/16/2003 | WO2002053701A3 Epididymal lipocalin gene and uses thereof |
| 01/16/2003 | WO2002051389A3 Aerogel powder comprising therapeutic agents |
| 01/16/2003 | WO2002046362A3 Gene associated with benign prostatic hyperplasia in humans |
| 01/16/2003 | WO2002042445A3 Differentiated cells suitable for human therapy |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002040016A3 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 01/16/2003 | WO2002038587A3 Haplotypes of the grm8 gene |
| 01/16/2003 | WO2002036743A3 Antisense modulation of calreticulin expression |
| 01/16/2003 | WO2002031144A3 Identification of cytotoxic activity from the ink of aplysia punctata |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002029026A3 Human proteases and polynucleotides encoding the same |
| 01/16/2003 | WO2002026782A3 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 01/16/2003 | WO2002022862A3 Methods for identifying modulators of protein interactions |
| 01/16/2003 | WO2002022808A3 Cripto mutant and uses thereof |
| 01/16/2003 | WO2002022806A3 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 01/16/2003 | WO2002022107A3 Pharmaceutical composition having modified carrier |
| 01/16/2003 | WO2002022080A8 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| 01/16/2003 | WO2002021141A3 Methods and compositions for diseases associated with amyloidosis |
| 01/16/2003 | WO2002020813A3 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 01/16/2003 | WO2002020047A3 Chlamydial peptides and their mimics in demyelinating disease |
| 01/16/2003 | WO2002018584A3 Xage-1, a gene expressed in multiple cancers, and uses thereof |
| 01/16/2003 | WO2002016616A3 Human carboxylesterase family member and uses thereof |
| 01/16/2003 | WO2002016595A3 Kidney-specific protein |
| 01/16/2003 | WO2002016587A3 Microtubule-associated proteins and tubulins |
| 01/16/2003 | WO2002016578A3 Secreted proteins and methods of using same |
| 01/16/2003 | WO2002014352A3 Therapeutic compounds for ovarian cancer |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002010406A3 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| 01/16/2003 | WO2002010200A3 Pas domain proteins |
| 01/16/2003 | WO2002008275A3 Genes expressed in obese rat hypothalamus |
| 01/16/2003 | WO2002007774A3 Methods for therapy of neurodegenerative disease of the brain |
| 01/16/2003 | WO2002004021A9 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/16/2003 | WO2002004005A3 Short peptides comprising histidine or alanine and their therapeutic use |
| 01/16/2003 | WO2002002772A3 Human extracellular matrix (ecm)-related tumor marker |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | WO2001095874A3 Highly efficient delivery of a large therapeutic mass aerosol |
| 01/16/2003 | WO2001094584A3 21784, a novel human calcium channel family member and uses thereof |
| 01/16/2003 | WO2001093913A3 T cell receptor fusions and conjugates and methods of use thereof |
| 01/16/2003 | WO2001092490A3 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 01/16/2003 | WO2001091739A3 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 01/16/2003 | WO2001090192A3 Bispecific immunoglobulin-like antigen binding proteins and method of production |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001087937A3 G-protein coupled receptors |
| 01/16/2003 | WO2001085767A3 Human proteins polynucleotides encoding them and methods of using the same |
| 01/16/2003 | WO2001074898A3 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 01/16/2003 | WO2001072833A3 Human ephrin-like receptor |
| 01/16/2003 | WO2001070174A8 Vegf-modulated genes and methods employing them |
| 01/16/2003 | WO2001068880A9 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 01/16/2003 | WO2001068805A9 Human olfactory receptors and genes encoding same |
| 01/16/2003 | WO2001068123A9 Monocyte chemoattractant activity of galectin-3 |
| 01/16/2003 | WO2001064944A9 MODULATION OF PLEIOTROPHIN SIGNALING BY RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE β/$g(z) |
| 01/16/2003 | WO2001064880A9 Human dynamin 40322 |